Industry / Uganda
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Chloroquine Out Of Favour As Resistance Grows
October 2007 | Industry NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Uganda's National Drug Authority is to ban imports of anti-malarial drug chloroqine unless special permission is granted, following the publication of research showing the drug now proves ineffective for 40% of Ugandan's suffering from malaria. Even when used in combination with Roche's Fansidar (sulfadoxine + pyrimethamine), Plasmodium falciparum parasitic resistance to chloroquine still ran at